{"product_id":"ap2-t","title":"AP2-T","description":"\u003cp\u003eA dual GIP\/GLP-1 receptor agonist widely studied for metabolic research. Lyophilized (freeze-dried) form, verified 98%+ purity. Available in 15mg and 30mg vials.\u003c\/p\u003e\n\n\u003ch3\u003eWhat Is AP2-T?\u003c\/h3\u003e\n\u003cp\u003eAP2-T is research-grade tirzepatide — a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Originally developed as an investigational compound for metabolic research, tirzepatide has become one of the most widely studied peptides in clinical settings. Published research in \u003cem\u003eThe New England Journal of Medicine\u003c\/em\u003e and \u003cem\u003eThe Lancet\u003c\/em\u003e has documented its effects on glycemic control, body composition, and metabolic biomarkers.\u003c\/p\u003e\n\n\u003ch3\u003eHistory\u003c\/h3\u003e\n\u003cp\u003eTirzepatide was developed by Eli Lilly and Company, with the first clinical trial results published in 2018. The compound received regulatory approval in 2022 under the brand name Mounjaro for a specific clinical application, followed by additional approval as Zepbound in 2023. The SURPASS and SURMOUNT clinical trial programs generated extensive published data on tirzepatide's dual-incretin mechanism. It remains one of the most actively investigated compounds in metabolic research.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eFor research purposes only. Not for human consumption.\u003c\/em\u003e\u003c\/p\u003e","brand":"Protocol Aminos","offers":[{"title":"20MG","offer_id":44807950204973,"sku":null,"price":129.0,"currency_code":"COP","in_stock":true},{"title":"30MG","offer_id":44807950237741,"sku":null,"price":199.0,"currency_code":"COP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0744\/2232\/1197\/files\/Tirz20mg.webp?v=1777072944","url":"https:\/\/protocolaminos.com\/products\/ap2-t","provider":"Protocol Aminos","version":"1.0","type":"link"}